NZ602217A - Vaccines for influenza - Google Patents
Vaccines for influenzaInfo
- Publication number
- NZ602217A NZ602217A NZ602217A NZ60221711A NZ602217A NZ 602217 A NZ602217 A NZ 602217A NZ 602217 A NZ602217 A NZ 602217A NZ 60221711 A NZ60221711 A NZ 60221711A NZ 602217 A NZ602217 A NZ 602217A
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- carbon
- reducing terminus
- reducing
- lipid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 206010022000 influenza Diseases 0.000 title 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000003473 lipid group Chemical group 0.000 abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 2
- 150000002016 disaccharides Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000712461 unidentified influenza virus Species 0.000 abstract 2
- 101710154606 Hemagglutinin Proteins 0.000 abstract 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 1
- 101710176177 Protein A56 Proteins 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
- 239000000185 hemagglutinin Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31310110P | 2010-03-11 | 2010-03-11 | |
| PCT/US2011/027993 WO2011112871A1 (en) | 2010-03-11 | 2011-03-10 | Vaccines for pandemic influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ602217A true NZ602217A (en) | 2014-08-29 |
Family
ID=44170437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602217A NZ602217A (en) | 2010-03-11 | 2011-03-10 | Vaccines for influenza |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110305748A1 (https=) |
| EP (1) | EP2544718A1 (https=) |
| JP (2) | JP2013522231A (https=) |
| KR (1) | KR20130048208A (https=) |
| CN (1) | CN102946900A (https=) |
| AU (1) | AU2011224245B2 (https=) |
| BR (1) | BR112012022939A2 (https=) |
| CA (1) | CA2792369A1 (https=) |
| EA (1) | EA201290897A1 (https=) |
| MX (1) | MX2012010472A (https=) |
| NZ (1) | NZ602217A (https=) |
| SG (1) | SG183514A1 (https=) |
| WO (1) | WO2011112871A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| PL2811981T3 (pl) * | 2012-02-07 | 2019-09-30 | Infectious Disease Research Institute | Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania |
| JP5944210B2 (ja) * | 2012-04-18 | 2016-07-05 | 一般財団法人化学及血清療法研究所 | 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子が組み込まれたｂ５ｒ遺伝子欠損組換えワクシニアウイルス |
| EP3041478A4 (en) * | 2013-09-05 | 2017-04-26 | Immune Design Corp. | Vaccine compositions for drug addiction |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US20150086592A1 (en) | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| CN111375055B (zh) * | 2020-02-20 | 2021-09-03 | 陈宛莎 | 一种2019-nCoV亚单位疫苗组合物及其免疫方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4876197A (en) | 1983-02-22 | 1989-10-24 | Chiron Corporation | Eukaryotic regulatable transcription |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4925791A (en) | 1984-07-20 | 1990-05-15 | Celltech Limited | Eucaryotic expression vectors |
| US5352449A (en) | 1986-05-30 | 1994-10-04 | Cambridge Biotech Corporation | Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP0382271B1 (en) | 1989-02-04 | 1994-12-21 | Akzo Nobel N.V. | Tocols as adjuvant in vaccine |
| JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
| US6022726A (en) | 1992-02-03 | 2000-02-08 | Palese; Peter | Genetically engineered attenuated viruses |
| US5273965A (en) | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
| MX9304089A (es) | 1992-07-08 | 1994-01-31 | Schering Corp | Uso de gm-csf como una vacuna adyuvante. |
| US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| DE9319879U1 (de) | 1993-12-23 | 1994-03-17 | Ems-Inventa AG, Zürich | Sequentiell Coextrudierte Kühlflüssigkeitsleitung |
| US5718904A (en) | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
| US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
| GB9809666D0 (en) | 1998-05-06 | 1998-07-01 | Isis Innovation | Modified viruses |
| HK1039072A1 (zh) | 1998-05-07 | 2002-04-12 | 科里克萨有限公司 | 佐剂组合物及其使用方法 |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US20060024670A1 (en) | 2004-05-18 | 2006-02-02 | Luke Catherine J | Influenza virus vaccine composition and methods of use |
| EP3332803B1 (en) | 2004-06-01 | 2021-09-08 | Icahn School of Medicine at Mount Sinai | Genetically engineered swine influenza virus and uses thereof |
| WO2006088481A2 (en) | 2005-02-15 | 2006-08-24 | Mount Sinai School Of Medicine Of New York University | Genetically engineered equine influenza virus and uses thereof |
| HRP20140488T1 (hr) * | 2006-07-17 | 2014-07-04 | Glaxosmithkline Biologicals S.A. | Cjepivo protiv influence |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| PT2468300T (pt) * | 2006-09-26 | 2018-01-30 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
| US8202967B2 (en) * | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| JP2007314538A (ja) * | 2007-05-23 | 2007-12-06 | Protein Sciences | インフルエンザ血球凝集素多価ワクチンの製造方法 |
| WO2009035528A2 (en) | 2007-09-07 | 2009-03-19 | University Of Georgia Research Foundation, Inc. | Synthetic lipid a derivative |
| WO2009092038A1 (en) | 2008-01-16 | 2009-07-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza dna vaccination and methods of use thereof |
| CN102481312B (zh) | 2009-06-05 | 2015-07-15 | 传染性疾病研究院 | 合成的吡喃葡萄糖脂佐剂 |
-
2011
- 2011-03-10 US US13/045,245 patent/US20110305748A1/en not_active Abandoned
- 2011-03-10 CN CN2011800232817A patent/CN102946900A/zh active Pending
- 2011-03-10 AU AU2011224245A patent/AU2011224245B2/en not_active Ceased
- 2011-03-10 SG SG2012063509A patent/SG183514A1/en unknown
- 2011-03-10 EA EA201290897A patent/EA201290897A1/ru unknown
- 2011-03-10 NZ NZ602217A patent/NZ602217A/en not_active IP Right Cessation
- 2011-03-10 WO PCT/US2011/027993 patent/WO2011112871A1/en not_active Ceased
- 2011-03-10 EP EP11715321A patent/EP2544718A1/en not_active Withdrawn
- 2011-03-10 CA CA2792369A patent/CA2792369A1/en not_active Abandoned
- 2011-03-10 KR KR1020127025971A patent/KR20130048208A/ko not_active Ceased
- 2011-03-10 MX MX2012010472A patent/MX2012010472A/es unknown
- 2011-03-10 JP JP2012557263A patent/JP2013522231A/ja active Pending
- 2011-03-10 BR BR112012022939A patent/BR112012022939A2/pt not_active IP Right Cessation
-
2016
- 2016-02-29 JP JP2016037168A patent/JP2016104815A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011224245B2 (en) | 2014-12-04 |
| CN102946900A (zh) | 2013-02-27 |
| EA201290897A1 (ru) | 2013-03-29 |
| WO2011112871A1 (en) | 2011-09-15 |
| AU2011224245A1 (en) | 2012-09-27 |
| US20110305748A1 (en) | 2011-12-15 |
| BR112012022939A2 (pt) | 2016-08-02 |
| SG183514A1 (en) | 2012-10-30 |
| JP2013522231A (ja) | 2013-06-13 |
| MX2012010472A (es) | 2012-11-30 |
| EP2544718A1 (en) | 2013-01-16 |
| JP2016104815A (ja) | 2016-06-09 |
| KR20130048208A (ko) | 2013-05-09 |
| CA2792369A1 (en) | 2011-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602217A (en) | Vaccines for influenza | |
| Goff et al. | Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses | |
| Joseph et al. | A new intranasal influenza vaccine based on a novel polycationic lipid—ceramide carbamoyl-spermine (CCS): I. Immunogenicity and efficacy studies in mice | |
| US20200376111A1 (en) | Vaccine composition | |
| US9220767B2 (en) | Vaccine composition for use against influenza | |
| Ghendon et al. | Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines | |
| JPWO2013151044A1 (ja) | 穿刺装置及びその製造方法 | |
| BRPI0720667A8 (pt) | Métodos de administração de vacina | |
| MX2010009351A (es) | Particulas similares a virus cristalizadas con azucar. | |
| IL276210B2 (en) | Mers-cov vaccine | |
| Kumar et al. | Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus | |
| WO2009092038A8 (en) | Influenza dna vaccination and methods of use thereof | |
| AU2011280259A8 (en) | Influenza vaccine | |
| JP2013522231A5 (https=) | ||
| BRPI0918806A2 (pt) | composição compreendendo quitosana para administração ocular de vaninas em aves | |
| AR073265A1 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
| NZ712713A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| Bai et al. | Development of semisynthetic saponin immunostimulants | |
| WO2012073257A3 (en) | Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals | |
| Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
| MX2013003545A (es) | Peptidos del veneno de escorpion rhopalorus junceus y composicion farmaceutica. | |
| EA201170569A1 (ru) | Лекарственное средство для повышения дозы противоаллергической вакцины | |
| WO2010106557A3 (en) | Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof | |
| JP2013506682A5 (https=) | ||
| Saravolac et al. | Immunoprophylactic strategies against respiratory influenza virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2016 BY CPA GLOBAL Effective date: 20150129 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2017 BY CPA GLOBAL Effective date: 20160129 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2018 BY CPA GLOBAL Effective date: 20170127 |
|
| LAPS | Patent lapsed |